RALEIGH, N.C., Feb. 12 /PRNewswire-FirstCall/ -- CLOSURE Medical
Corporation (Nasdaq: CLSR), a medical tissue adhesive products company, today
announced that it intends to release financial results for the fourth quarter
and year-ended December 31, 2001, on Tuesday, February 19, 2002. In
conjunction with this release CLOSURE will host a conference call that will be
broadcast live over the Internet at 4:30 p.m. ET on Tuesday, February 19,
2002.
Individuals wishing to participate on the webcast can access the event at
http://www.closuremed.com . Please allow extra time prior to the call to
download the streaming media software required for listening to the Internet
broadcast. The online archive of the broadcast will be available within 2
hours of the live call and will be available for replay.
About CLOSURE Medical
CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
develops, manufactures, and commercializes medical tissue adhesive products
based on its proprietary cyanoacrylate technology. CLOSURE's proprietary
technology has customized the physical and chemical properties of
cyanoacrylates to develop medical adhesive formulations to close and seal
topical skin wounds and incisions. In addition, CLOSURE is currently
developing internal adhesive formulations to close or seal internal wounds and
an adhesive formulation for the possible treatment of emphysema.
DERMABOND Topical Skin Adhesive is a topical tissue adhesive used to close
wounds from skin lacerations and incisions, minimally invasive surgery and
plastic surgery. DERMABOND adhesive can be used as a replacement for topical
sutures or staples and is marketed and distributed by ETHICON, Inc., a Johnson
& Johnson company and the world leader in wound closure products.
BAND-AID(R) Brand Liquid Bandage is the first and only cyanoacrylate
medical device approved by the FDA for the over-the-counter ("OTC") adhesive
bandage market. BAND-AID(R) Brand Liquid Bandage is painted on the wound,
sealing it from dirt and germs and creating a healing environment which allows
natural healing to take place quickly. As the wound heals, the adhesive
sloughs off naturally. CLOSURE has signed a worldwide supply, distribution
and development rights agreement with Johnson & Johnson Consumer Products
Company which includes rights to BAND-AID(R) Brand Liquid Bandage and
distribution rights to all present and future OTC products, except for SOOTHE-
N-SEAL(R) adhesive. Distribution of BAND-AID(R) Brand Liquid Bandage by
Johnson & Johnson Consumer Products Company is underway.
SOOTHE-N-SEAL(R) adhesive is indicated for the treatment of oral ulcers
and mouth sores. It forms a protective barrier that shields oral ulcers from
irritation due to eating and drinking while providing immediate and long-term
pain relief. SOOTHE-N-SEAL(R) adhesive is distributed to the professional and
consumer markets by Colgate Oral Pharmaceuticals, Inc.
The NEXABAND(R) liquid adhesive line consists of two products used in
veterinary wound closure and wound care. The adhesives are used in cat declaw
procedures as well as spay and neuter procedures. In July 2001, the Company
entered into an agreement providing Abbott Laboratories with worldwide supply,
distribution and development rights to the NEXABAND(R) product line. In
accordance with the agreement, Abbott has been granted immediate worldwide
distribution rights of NEXABAND(R) adhesives excluding the United States and
Canada. Upon the expiration of the Company's prior distribution arrangement
in the second quarter of 2002, Abbott can begin the distribution of
NEXABAND(R) products in the United States and Canada.
In November 2001, the Company entered into an agreement providing Johnson
& Johnson Wound Management, a division of ETHICON, Inc., a Johnson & Johnson
company, with worldwide supply, distribution and development rights to the
Company's professional wound management platform, including the novel Liquid
Occlusive Dressing ("LOD") for the treatment of partial thickness wounds. The
agreement is in the form of an amendment to the terms of its existing
licensing and development agreement with ETHICON, Inc.
DERMABOND adhesive is a registered trademark of ETHICON, Inc.; SOOTHE-N-
SEAL(R) is a registered trademark of Colgate Oral Pharmaceuticals, Inc.; BAND-
AID(R) Brand Liquid Bandage is a registered trademark of Johnson & Johnson;
and NEXABAND(R) is a registered trademark of CLOSURE Medical Corporation.
This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company products; the progress of its research and development programs for
future products; the need for regulatory approval and effects of governmental
regulation; technological uncertainties; the satisfactory conclusion of
negotiations with, and dependence on marketing partners, and dependence on
patents and trade secrets, as well as those detailed in the Company's Annual
Report on Form 10-K for the year ended December 31, 2000 filed with the
Securities and Exchange Commission.
SOURCE CLOSURE Medical Corporation
 back to top
Related links:
http://www.closuremed.com
CONTACT:
Robert V. Toni, President & CEO, or Benny
Ward, CFO, both of CLOSURE Medical Corporation, +1-919-876-7800,
or General Info, Alison Ziegler, Analyst Info, Julie Tu, or Media
Info, Judith Sylk-Siegel, of FRB Weber Shandwick, +1-212-445-8400
|
